Image pharmaphorum Editor Oncology Checkpoint inhibitors, Enhertu in spotlight as ASCO resumes ... Researchers also dove into socio-economic disparities in cancer care. Oncology Phesi’s Dr Gen Li: New approaches to clinical trials in canc... Dr Gen Li, founder and president of Phesi, a provider of AI-powered clinical development analytics, products and solutions, discusses some of the latest challenges facing the industry, incl Oncology Realising the promise of cancer vaccines For years, the promise of therapeutic cancer vaccines has intrigued researchers working in the oncology space. And for good reason. Oncology New horizons in breast cancer care Interview with Markus Kosch, Daiichi Sankyo head of Oncology Business Division in Europe. Load more results
Oncology Checkpoint inhibitors, Enhertu in spotlight as ASCO resumes ... Researchers also dove into socio-economic disparities in cancer care.
Oncology Phesi’s Dr Gen Li: New approaches to clinical trials in canc... Dr Gen Li, founder and president of Phesi, a provider of AI-powered clinical development analytics, products and solutions, discusses some of the latest challenges facing the industry, incl
Oncology Realising the promise of cancer vaccines For years, the promise of therapeutic cancer vaccines has intrigued researchers working in the oncology space. And for good reason.
Oncology New horizons in breast cancer care Interview with Markus Kosch, Daiichi Sankyo head of Oncology Business Division in Europe.
News Pulmonary fibrosis drug developer Avalyn files IPO Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
